What's Happening?
Innate Pharma is set to present interim results from its MATISSE Phase 2 study at the AACR Annual Meeting 2026. The study evaluates IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy for resectable
non-small cell lung cancer (NSCLC). The interim analysis of 40 patients showed promising results, with higher pathological complete response rates compared to the benchmark set by durvalumab plus chemotherapy alone. The study continues to recruit patients with tumors expressing PD-L1≥1%, aiming to enhance anti-tumor immune responses and improve clinical outcomes in early-stage lung cancer.
Why It's Important?
The promising results from the MATISSE trial could represent a significant advancement in the treatment of resectable NSCLC, particularly for patients with PD-L1 positive tumors. By targeting the CD39 and PD-L1 pathways, the combination therapy could offer a more effective treatment option, potentially reducing the risk of cancer recurrence. This development is crucial as it addresses the unmet need for novel perioperative treatment strategies in lung cancer, which remains a leading cause of cancer-related deaths worldwide.
What's Next?
As the study progresses, further data will be collected to confirm the efficacy and safety of the combination therapy. The results will be closely monitored by the medical community, and if successful, could lead to changes in treatment protocols for NSCLC. Innate Pharma, in collaboration with AstraZeneca, will continue to explore the potential of IPH5201 in enhancing anti-tumor immunity, with the possibility of expanding its application to other cancer types.
